On November 18, 2026 Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported that its next-generation sequencing (NGS)-based clonoSEQ test for measurable residual disease (MRD) assessment will be featured in approximately 100 abstracts, including 27 oral presentations, at the 68th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper), taking place Dec. 12–15, 2026, in New Orleans.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The research at this year’s meeting reflects the continued evolution of MRD assessment across hematologic malignancies, moving beyond measuring the depth of treatment response to informing how therapies are developed, evaluated, and adapted based on individual patient response. Across 20 unique biopharma-sponsored studies featuring clonoSEQ, MRD is utilized as a primary endpoint in four studies and a secondary endpoint in 11, underscoring how highly sensitive MRD assessment has become integral to evaluating therapeutic efficacy and advancing new treatment approaches.
Key highlights include:
Advancing MRD-informed treatment strategies in multiple myeloma: At ASH (Free ASH Whitepaper), data from pivotal Phase 3 studies, including PERSEUS, AURIGA, and BENEFIT, reinforce clonoSEQ’s established role in evaluating treatment response, while research from PERSEUS and IMMUNOPLANT highlights its use in informing treatment strategies, including maintenance de-escalation and consolidation therapy. Additionally, real-world research from the Icahn School of Medicine at Mount Sinai leveraging clonoSEQ data identifies patients with sustained MRD negativity and survival comparable to the general population, highlighting the ability to inform treatment discontinuation and providing new evidence supporting the possibility of cure in multiple myeloma.
Evaluating MRD-guided treatment in chronic lymphocytic leukemia (CLL): Several studies, including the Phase 3 MAJIC study, demonstrate the use of clonoSEQ in guiding the duration of therapy and assessing response. In addition, in the MIRACLE study, MRD is also used as a primary endpoint.
Strengthening MRD testing utility relative to PET/CT in lymphoma: New real-world data from Adaptive, Hackensack University Medical Center, and the University of Nebraska Medical Center, as well as study data from Wilmot Cancer Center, show the prognostic value of clonoSEQ MRD assessment following frontline treatment in diffuse large B-cell lymphoma (DLBCL), including its ability to complement imaging.
"The research being presented at ASH (Free ASH Whitepaper) underscores clonoSEQ’s established position in pivotal clinical trials and showcases its ever-expanding role as a tool to inform patient care strategies across blood cancers," said Susan Bobulsky, chief commercial officer, MRD, Adaptive Biotechnologies. "Multiple myeloma offers a powerful example of this progress, with updated clinical guidelines, a new definition of cure, and important Phase 3 research reinforcing the value of systematic MRD assessment. With a strong foundation of clinical evidence, regulatory validation and unparalleled real-world patient experience, Adaptive is helping shape the future of MRD-guided care for blood cancer patients."
A list of selected abstracts featuring clonoSEQ is available here.
About clonoSEQ
clonoSEQ is the first and only FDA-cleared in vitro diagnostic (IVD) test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in patients with chronic lymphocytic leukemia (CLL) using blood or bone marrow. clonoSEQ is also available in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), T-cell acute lymphoblastic leukemia (T-ALL), and other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL.
clonoSEQ identifies and quantifies DNA sequences in malignant cells—detecting one cancer cell in one million healthy cells—to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier.
clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR). For intended use details in the EU, see the instructions for use, available on request. To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.
(Press release, Adaptive Biotechnologies, NOV 18, 2026, View Source [SID1234674942])